Information  X 
Enter a valid email address

Titon Holdings PLC (TON)

  Print      Mail a friend       Annual reports

Monday 10 December, 2018

Titon Holdings PLC

Admission to trading on AIM

RNS Number : 8005J
Titon Holdings PLC
10 December 2018
 

10 December 2018

Titon Holdings plc     

Admission to trading on AIM

Further to the announcement on 9 November 2018, Titon Holdings plc ("Titon" or the "Company") is pleased to confirm that admission of its ordinary shares of 10 pence each ("Ordinary Shares") to trading on the AIM market of the London Stock Exchange will take place at 8.00am today ("Admission"). At the same time, the admission of the Ordinary Shares to the premium listing segment of the Official List and to trading on the Main Market will be cancelled. The ordinary shares will continue to trade under the TIDM "TON".

Disclosures as required by AIM Rule 26 can be found at: http://www.titonholdings.com/pages/shareholder-info/aim-rule-26-information.php 

The Company's issued share capital comprises 11,133,750 Ordinary Shares, each carrying the right to one vote. The Company holds 50,000 Ordinary Shares in treasury. Accordingly, the Company's issued share capital (excluding Ordinary Shares held in treasury) consists of 11,083,750 Ordinary Shares. This figure of 11,083,750 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information please contact:

 

Titon Holdings plc

Keith Ritchie, Executive Chairman

 

Tel: +44 (0)1206 713821



Shore Capital (Nominated Adviser and Broker)

Dru Danford

Edward Mansfield

Daniel Bush

Tel: +44 (0)20 7408 4090



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCGIBDDRXGBGIR

a d v e r t i s e m e n t